Omalizumab treatment reduces asthma exacerbations regardless of airway bronchodilator reversibility

J Allergy Clin Immunol Pract. 2022 Aug;10(8):2181-2183.e1. doi: 10.1016/j.jaip.2022.04.029. Epub 2022 May 6.

Authors

Samuel DeLeon¹, Franco Barsanti¹, Cecile T J Holweg², Bongin Yoo², Blaine Creasy², Michael E Wechsler³

Affiliations

¹ Urban Health Plan Inc., Bronx, NY.
² Genentech, Inc., South San Francisco, Calif.
³ Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colo. Electronic address: wechslerm@njhealth.org.

PMID: 35526776
DOI: 10.1016/j.jaip.2022.04.029

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Asthmatic Agents* / therapeutic use
Asthma* / drug therapy
Bronchodilator Agents / therapeutic use
Humans
Omalizumab / therapeutic use
Respiratory System
Treatment Outcome

Substances

Anti-Asthmatic Agents
Bronchodilator Agents
Omalizumab

Associated data

ClinicalTrials.gov/NCT01922037